Pentamycin Purification via Morpholine Solvate Crystallization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Pentamycin's chemical instability and impurity challenges hinder its purification beyond 93% purity, making it difficult to reintroduce into the pharmaceutical market due to sensitivity to light, moisture, and structural similarities with impurities, which complicates separation and stabilization.

Innovation Solution

Formation of solvates with small polar heterocycles like morpholine and N-methylpyrrolidone in alcoholic solvents, followed by crystallization and purification processes to achieve purity exceeding 95%, specifically transforming needle-shaped into flake-shaped morpholine solvates for effective purification and stabilization of pentamycin.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Manufacturing precision

If conventional purification methods are used, then pentamycin can be obtained, but purity cannot exceed 93% due to co-crystallization of impurities

Engineering Contradiction:
ImprovepurityVSAvoidpurification difficulty
Core Design Contradiction:
Manufacturing precisionVSEase of manufacture

Solution Approach 1:

The patent uses small polar heterocycles (morpholine, N-methylpyrrolidone, N-ethylpyrrolidone) as intermediary solvents to form solvates with pentamycin. These solvates have different crystallization behaviors than pure pentamycin, allowing impurities to be excluded from the crystal lattice. The solvate acts as an intermediate form that facilitates purification beyond the 93% barrier, after which the heterocycle is removed to yield highly pure pentamycin.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the physical and chemical parameters of the purification process by introducing specific heterocyclic compounds that alter the solubility and crystallization characteristics of pentamycin. By controlling the type of heterocycle used and the crystallization conditions (temperature, solvent ratios), the process achieves separation of impurities that cannot be removed by conventional methods alone.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If pentamycin is purified to high purity, then stability against degradation improves, but the process becomes more complex due to multiple purification steps

Engineering Contradiction:
ImprovestabilityVSAvoidprocess complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The heterocyclic solvates serve as intermediaries that simplify the overall process. Rather than requiring multiple sequential purification steps to achieve high purity, the solvate formation step consolidates the purification function into a single operation. The solvate crystallization inherently excludes impurities, and subsequent removal of the heterocycle yields stable, high-purity pentamycin in one streamlined process flow.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Ease of manufacture

If conventional crystallization is used, then purification is simple, but impurities with similar physical properties cannot be separated

Engineering Contradiction:
Improvepurification simplicityVSAvoidseparation efficiency
Core Design Contradiction:
Ease of manufactureVSManufacturing precision

Solution Approach 1:

The heterocyclic compounds act as mediators that exploit subtle differences in molecular interactions between pentamycin and its impurities. By forming solvates with specific heterocycles, the process creates a crystallization environment where even minor differences in physical properties result in significant separation efficiency, overcoming the limitation of conventional crystallization methods.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The process successfully achieves pentamycin purity exceeding 96% and significantly reduces degradation rates, enabling its stable use in pharmaceutical formulations for treating fungal infections.

Implementation Method 1

Formation of solvates with small polar heterocycles like morpholine and N-methylpyrrolidone in alcoholic solvents, followed by crystallization and purification processes

Methodology Applied
Scientific EffectSolvation: Solvation

Implementation Method 2

followed by crystallization and purification processes to achieve purity exceeding 95%

Methodology Applied
Scientific EffectCrystallization: Crystallisation

Data Source

PatentEP2271655B1Highly pure pentamycin
Publication Date: 2013.10.09 LUMAVITA AG
  • EP2271655B1 patent drawingFigure 1~2
  • EP2271655B1 patent drawingFigure 3~4
  • EP2271655B1 patent drawingFigure 5~6

AI summary

Described is pentamycin in a purity exceeding 95%, certain polymorphs and solvates of pentamycin, processes for their manufacture, and a method for decreasing the rate of degradation of pentamycin.